NCT03170206View on ClinicalTrials.gov

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

February 28, 2023

Study Completion Date

December 31, 2025

Conditions
Lung Cancer
Interventions
DRUG

Binimetinib

Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow.

DRUG

Palbociclib

It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (2)

Pfizer
Array BioPharma
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Array BioPharma

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER